Heart failure & cardiomyopathiesMeta-analysis
Prevalence of cardiac amyloidosis in screening studies: a systematic review and meta-analysis
- systematic review and meta-analysis
- random-effects meta-analysis
Authors' conclusion
This meta-analysis shows that CA is relatively frequent in HFpEF/HFmrEF, severe AS, and LVH/HCM. To obtain reliable population estimates, future studies should test either all eligible participants or a predefined random sample, rather than only those with suspected disease. In clinical practice, screening strategies should clearly define which higher-risk individuals are referred for second-level tests, balancing diagnostic yield with feasibility.
Study context
- Population
- Screening studies of cardiac amyloidosis (CA) across clinical settingsstudies included
- Participants
- Eighty-three studies
- Comparison
- whole cohort vs tested subgroup
Pooled result
As reported in the abstract
Further pooled results
Pooled CA prevalence in heart failure (HF)-mainly HFpEF/HFmrEF
Pooled CA prevalence in aortic stenosis (AS)
Pooled CA prevalence in orthopaedic cohorts
Pooled CA prevalence with 'no specific red flags'
Pooled CA prevalence in non-cardiac bone scintigraphy
- Prevalence in both denominators
- 0.49%
CA type
- Across settings, transthyretin CA predominated over light-chain CA
Systematic screening in the general elderly
- Several studies approached systematic screening in the general elderly; they were few and still applied referral criteria to second-level examinations
Original publication
Summarised from the published abstract; every number is checked against it